AstraZeneca $AZN
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS289
PHASE 3 / 2-3175
RECRUITING124
READOUTS ≤12 MONTHS58
READOUT SLIPPED >6 MO49%
Delay Index: of 226 active trials registered more than a year ago, 110 have moved their primary completion (readout) date by more than 6 months since first registration (median +5.4 months). See all sponsors →
Open AstraZeneca on the live radar map → 📅 $AZN readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| CONFIRM NCT00099437 |
P3 | Active, not recruiting | Breast Cancer | 736 | 2009-02-27 |
| olaparib NCT01081951 |
P2 | Active, not recruiting | Ovarian Cancer | 162 | 2011-10-10 (+1 mo) |
| SELECT-1 NCT01933932 |
P3 | Active, not recruiting | Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV | 510 | 2016-06-07 |
| Olaparib 300mg tablets NCT01874353 |
P3 | Active, not recruiting | Platinum Sensitive; BRCA Mutated | 327 | 2016-09-19 (+15 mo) |
| SOLO-1 NCT01844986 |
P3 | Active, not recruiting | Newly Diagnosed; Advanced Ovarian Cancer | 450 | 2018-05-17 (+23 mo) |
| MYSTIC NCT02453282 |
P3 | Active, not recruiting | Non-Small-Cell Lung Carcinoma NSCLC | 1118 | 2018-10-04 (+17 mo) |
| Savolitinib NCT03091192 |
P3 | Active, not recruiting | Carcinoma; Carcinoma, Renal Cell | 60 | 2019-08-18 (-18 mo) |
| CASPIAN NCT03043872 |
P3 | Active, not recruiting | Small Cell Lung Carcinoma Extensive Disease | 987 | 2020-01-27 |
| MEDI4736 (Durvalumab) NCT02516241 |
P3 | Active, not recruiting | Urothelial Cancer | 1126 | 2020-01-27 (+27 mo) |
| OlympiA NCT02032823 |
P3 | Active, not recruiting | Breast Cancer | 1837 | 2020-03-27 |
| NEPTUNE NCT02542293 |
P3 | Active, not recruiting | Non Small Cell Lung Carcinoma NSCLC | 953 | 2020-09-21 (+26 mo) |
| BAYOU NCT03459846 |
P2 | Active, not recruiting | Urinary Bladder Neoplasms | 154 | 2020-10-15 (+13 mo) |
| Olaparib Continuous (28-Day cycle) 300 mg BD. NCT03330847 |
P2 | Active, not recruiting | Metastatic Triple Negative Breast Cancer | 273 | 2020-11-13 (+1 mo) |
| ORION NCT03775486 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer NSCLC | 401 | 2021-01-11 (+4 mo) |
| POSEIDON NCT03164616 |
P3 | Active, not recruiting | Non Small Cell Lung Cancer NSCLC | 1186 | 2021-03-12 (+19 mo) |
| olaparib NCT03732820 |
P3 | Active, not recruiting | Metastatic Castration-resistant Prostate Cancer | 895 | 2021-07-30 (+4 mo) |
| TOPAZ-1 NCT03875235 |
P3 | Active, not recruiting | Biliary Tract Neoplasms | 810 | 2021-08-11 (-7 mo) |
| HIMALAYA NCT03298451 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 1324 | 2021-08-27 (+18 mo) |
| MEDIOLA NCT02734004 |
P1/2 | Active, not recruiting | Ovarian; Breast | 264 | 2021-09-17 (+27 mo) |
| ADAURA NCT02511106 |
P3 | Active, not recruiting | Stage IB-IIIA Non-small Cell Lung Carcinoma | 682 | 2022-04-11 (+9 mo) |
| INTERLINK-1 NCT04590963 |
P3 | Active, not recruiting | Squamous Cell Carcinoma of the Head and Neck | 370 | 2022-05-11 (-23 mo) |
| TAZMAN NCT04745689 |
P2 | Active, not recruiting | Small-Cell Lung Cancer | 31 | 2022-06-18 (-14 mo) |
| SERENA-2 NCT04214288 |
P2 | Active, not recruiting | Advanced ER-Positive HER2-Negative Breast Cancer | 240 | 2022-08-30 (+5 mo) |
| Durvalumab (MEDI4736) NCT03003962 |
P3 | Active, not recruiting | Non Small Cell Lung Carcinoma NSCLC | 669 | 2022-10-27 (+28 mo) |
| AEGEAN NCT03800134 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 825 | 2022-11-10 (+27 mo) |
| CoC NCT04606771 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer | 30 | 2022-12-21 (+7 mo) |
| Acalabrutinib NCT03932331 |
P1/2 | Active, not recruiting | Phase I: Relapsed or Refractory B-cell Malignancies; Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | 105 | 2022-12-22 (+27 mo) |
| DPT01 NCT04639219 |
P2 | Active, not recruiting | Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast | 102 | 2023-01-25 (+3 mo) |
| Durvalumab / Tremelimumab Combination Therapy NCT03837899 |
P1/2 | Active, not recruiting | Pediatric Cancer; Solid Tumor Pediatric | 50 | 2023-02-28 (+17 mo) |
| FLAURA2 NCT04035486 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 587 | 2023-04-03 |
| CAPItello-291 NCT04305496 |
P3 | Active, not recruiting | Locally Advanced (Inoperable) or Metastatic Breast Cancer | 818 | 2023-05-09 (+5 mo) |
| MANDARA NCT04157348 |
P3 | Active, not recruiting | Eosinophilic Granulomatous Vasculitis | 140 | 2023-08-10 (+13 mo) |
| EMERALD-1 NCT03778957 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 724 | 2023-09-11 (+29 mo) |
| Datopotamab Deruxtecan (Dato-DXd) NCT05460273 |
P1/2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Cancer | 119 | 2023-11-07 (-1 mo) |
| Acalabrutinib NCT04075292 |
P3 | Active, not recruiting | Untreated Chronic Lymphocytic Leukemia | 155 | 2024-01-03 (+10 mo) |
| LAURA NCT03521154 |
P3 | Active, not recruiting | Non Small Cell Lung Cancer (Stage III) | 216 | 2024-01-05 (+26 mo) |
| ADRIATIC NCT03703297 |
P3 | Active, not recruiting | Small Cell Lung Cancer | 730 | 2024-01-15 (+31 mo) |
| olaparib NCT05171816 |
P3 | Active, not recruiting | Metastatic Castration-resistant Prostate Cancer | 110 | 2024-01-22 (-2 mo) |
| DESTINY-B12 NCT04739761 |
P3 | Active, not recruiting | Breast Cancer | 506 | 2024-02-08 (-3 mo) |
| DB-06 NCT04494425 |
P3 | Active, not recruiting | Advanced or Metastatic Breast Cancer | 866 | 2024-03-18 (+15 mo) |
| MONETTE NCT05061134 |
P2 | Active, not recruiting | Melanoma | 194 | 2024-04-12 (+4 mo) |
| NIAGARA NCT03732677 |
P3 | Active, not recruiting | Muscle Invasive Bladder Cancer | 1063 | 2024-04-29 (-20 mo) |
| PACIFIC-5 NCT03706690 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 407 | 2024-06-23 (+39 mo) |
| DUO-E NCT04269200 |
P3 | Active, not recruiting | Endometrial Neoplasms | 805 | 2024-07-08 (+13 mo) |
| Dato-DXd NCT05104866 |
P3 | Active, not recruiting | Breast Cancer | 732 | 2024-07-24 (+12 mo) |
| LOTOS NCT05941897 |
P2 | Active, not recruiting | Advanced or Metastatic NSCLC | 39 | 2024-07-29 |
| KOMET NCT04924608 |
P3 | Active, not recruiting | Neurofibromatosis 1; Plexiform Neurofibroma (PN) | 145 | 2024-08-05 (+8 mo) |
| SAVANNAH NCT03778229 |
P2 | Active, not recruiting | Carcinoma | 367 | 2024-08-23 (+43 mo) |
| HUDSON NCT03334617 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer | 528 | 2024-09-13 (+50 mo) |
| AZD0171 NCT04999969 |
P2 | Active, not recruiting | Locally Advanced or Metastatic Solid Tumours | 126 | 2024-10-07 (+10 mo) |
| CAPItello-281 NCT04493853 |
P3 | Active, not recruiting | Hormone-Sensitive Prostate Cancer | 1012 | 2024-10-07 (+8 mo) |
| NeoADAURA NCT04351555 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 358 | 2024-10-15 (+9 mo) |
| COMPEL NCT04765059 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 98 | 2024-10-28 (+3 mo) |
| DL-05 NCT05246514 |
P2 | Active, not recruiting | HER2-mutant Non-Small Cell Lung Cancer | 72 | 2024-11-04 (+11 mo) |
| BEGONIA NCT03742102 |
P1/2 | Active, not recruiting | Triple Negative Breast Neoplasms | 243 | 2024-11-29 (+49 mo) |
| AZD7789 NCT04931654 |
P1/2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung; Gastric Cancer | 136 | 2024-12-04 (-5 mo) |
| Durvalumab NCT04592913 |
P3 | Active, not recruiting | Gastrointestinal Neoplasms; Esophagogastric Junction | 957 | 2024-12-20 (-2 mo) |
| DB-07 NCT04538742 |
P1/2 | Active, not recruiting | Metastatic Breast Cancer | 245 | 2025-01-31 (+14 mo) |
| Trastuzumab Deruxtecan NCT05113251 |
P3 | Active, not recruiting | Breast Neoplasms; Breast Cancer | 927 | 2025-03-12 (+13 mo) |
| DUO-O NCT03737643 |
P3 | Active, not recruiting | Advanced Ovarian Cancer | 1407 | 2025-03-17 (+34 mo) |
| POTOMAC NCT03528694 |
P3 | Active, not recruiting | Non-muscle-invasive Bladder Cancer | 1018 | 2025-04-03 (+40 mo) |
| ORCHARD NCT03944772 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer | 247 | 2025-05-06 |
| NATRON NCT04191304 |
P3 | Active, not recruiting | Hypereosinophilic Syndrome | 134 | 2025-05-07 (+34 mo) |
| PATAPSCO NCT05943106 |
P3 | Active, not recruiting | Non-Muscle- Invasive Bladder Cancer | 100 | 2025-06-16 (-25 mo) |
| SERENA-6 NCT04964934 |
P3 | Active, not recruiting | ER-Positive HER2-Negative Breast Cancer | 315 | 2025-06-30 (+21 mo) |
| Tulip SC NCT04877691 |
P3 | Active, not recruiting | Systemic Lupus Erythematosus | 367 | 2025-08-22 (+17 mo) |
| Dato-DXd NCT05374512 |
P3 | Active, not recruiting | Breast Cancer | 644 | 2025-08-25 (-3 mo) |
| TOURMALINE NCT05771480 |
P3 | Active, not recruiting | Biliary Tract Cancer | 142 | 2025-10-02 (-6 mo) |
| LATIFY NCT05450692 |
P3 | Active, not recruiting | Advanced or Metastatic Non-Small Cell Lung Cancer | 594 | 2025-10-06 (+4 mo) |
| SAMETA NCT05043090 |
P3 | Active, not recruiting | Papillary Renal Cell Carcinoma | 148 | 2025-12-31 (+22 mo) |
| MDT-BRIDGE NCT05925530 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer | 142 | 2026-01-12 (-3 mo) |
| PANDA NCT07128615 |
P1/2 | Active, not recruiting | Influenza A | 405 | 2026-01-28 |
| EMERALD-3 NCT05301842 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 760 | 2026-02-23 (+4 mo) |
| VOLGA NCT04960709 |
P3 | Active, not recruiting | Muscle Invasive Bladder Cancer | 712 | 2026-03-02 (+7 mo) |
| CAPItello280 NCT05348577 |
P3 | Active, not recruiting | Prostate Cancer | 1035 | 2026-03-04 (-5 mo) |
| CAPItello-290 NCT03997123 |
P3 | Active, not recruiting | Triple Negative Breast Neoplasms | 923 | 2026-03-16 (+54 mo) |
| SIERRA NCT05883644 |
P3 | Active, not recruiting | Advanced Hepatocellular Carcinoma | 111 | 2026-03-30 |
| AMALTHEA NCT06450197 |
P2 | Active, not recruiting | Moderate to Severe Crohn's Disease | 120 | 2026-04-30 |
| LADOGA NCT06606847 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer | 30 | 2026-05-04 (-2 mo) |
| EPIC-ATTR NCT06194825 |
P3 | Active, not recruiting | Transthyretin Amyloid Cardiomyopathy | 64 | 2026-05-13 (+14 mo) |
| AZD0901 NCT06346392 |
P3 | Active, not recruiting | Gastric Cancer; Gastroesophageal Junction Cancer | 594 | 2026-05-31 (+2 mo) |
| NILE NCT03682068 |
P3 | Active, not recruiting | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | 1246 | 2026-06-01 (+49 mo) |
| Trastuzumab Deruxtecan NCT05048797 |
P3 | Active, not recruiting | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 454 | 2026-06-09 (+17 mo) |
| SERENA-4 NCT04711252 |
P3 | Active, not recruiting | ER-Positive HER2-Negative Breast Cancer | 1371 | 2026-06-26 (+8 mo) |
| EMERALD-Y90 NCT06040099 |
P2 | Active, not recruiting | Hepatocellular Carcinoma (HCC) | 58 | 2026-06-30 (-3 mo) |
| SAFFRON NCT05261399 |
P3 | Active, not recruiting | Carcinoma; Non-Small-Cell Lung | 341 | 2026-07-06 (+13 mo) |
| NEOLA NCT06194448 |
P2 | Active, not recruiting | Lung Cancer | 76 | 2026-07-07 (-8 mo) |
| TROPION-Lung12 NCT06564844 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 25 | 2026-07-10 (-64 mo) |
| CROSSING NCT05583227 |
P3 | Active, not recruiting | Eosinophilic Esophagitis | 368 | 2026-07-14 (+2 mo) |
| MONO-OLA1 NCT04884360 |
P3 | Active, not recruiting | Ovarian Cancer | 366 | 2026-07-27 (+26 mo) |
| PACIFIC-8 NCT05211895 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 791 | 2026-08-10 (+5 mo) |
| CALLISTO NCT06681324 |
P2 | Active, not recruiting | Crohn's Disease | 24 | 2026-08-10 (+7 mo) |
| GAMBIT NCT07143604 |
P2 | Active, not recruiting | Gastric Cancer; Gastroesophageal Junction Cancer | 33 | 2026-08-14 (-1 mo) |
| eVOLVE-Lung02 NCT05984277 |
P3 | Active, not recruiting | Metastatic Non-small Cell Lung Cancer | 895 | 2026-08-17 (-21 mo) |
| ZODIAC NCT06942910 |
P2 | Active, not recruiting | Chronic Kidney Disease With High Proteinuria | 224 | 2026-09-26 (+2 mo) |
| TREMENDOUS NCT05557838 |
P3 | Active, not recruiting | Hepatocellular Carcinoma | 214 | 2026-09-30 (+18 mo) |
| ARIES NCT07717840 |
P1/2 | Active, not recruiting | RSV Respiratory Syncytial Virus | 164 | 2026-10-01 |
| AZD6234 NCT07017179 |
P2 | Active, not recruiting | Obesity/Overweight | 16 | 2026-10-23 (+3 mo) |
| Volrustomig NCT05775159 |
P2 | Active, not recruiting | Hepatocellular Carcinoma; Biliary Tract Cancer | 294 | 2026-10-27 (+24 mo) |
| TRITON NCT06008093 |
P2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 103 | 2026-10-27 (-1 mo) |
| CAPItrue NCT06635447 |
P3 | Active, not recruiting | Breast Cancer | 293 | 2026-10-31 (+6 mo) |
| LAVENDER NCT06015737 |
P3 | Active, not recruiting | Cutaneous Lupus Erythematosus | 339 | 2026-11-02 (+7 mo) |
| ANDROMEDA NCT07336446 |
P1/2 | Active, not recruiting | Prostate Cancer | 6 | 2026-11-05 |
| AZD0901 NCT06219941 |
P2 | Recruiting | Gastric Cancer; Gastroesophageal Junction Cancer | 226 | 2026-11-17 (+20 mo) |
| APOLLO NCT06267729 |
P1/2 | Recruiting | Metastatic Prostate Cancer | 60 | 2026-11-24 (-5 mo) |
| TREMENDOUS-2 NCT07081633 |
P2 | Active, not recruiting | Hepatocellular Carcinoma | 114 | 2026-11-30 |
| BaxDuo-Baltic NCT07222917 |
P2 | Active, not recruiting | Chronic Kidney Disease and Hypertension | 222 | 2026-12-10 (-5 mo) |
| DOMINICA NCT05692180 |
P3 | Active, not recruiting | Asthma | 94 | 2026-12-23 (-40 mo) |
| ROSY-D NCT05303532 |
P3 | Enrolling by invitation | Cancer | 214 | 2026-12-31 (+26 mo) |
| AZURE-HeFH NCT07000136 |
P3 | Active, not recruiting | Heterozygous Familial Hypercholesterolaemia | 473 | 2027-01-04 (-3 mo) |
| DAISY NCT05925803 |
P3 | Active, not recruiting | Systemic Sclerosis; Scleroderma | 314 | 2027-01-06 (-12 mo) |
| PACIFIC-9 NCT05221840 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 1051 | 2027-01-08 (+7 mo) |
| TROPION-Lung15 NCT06417814 |
P3 | Active, not recruiting | Metastatic Non-small Cell Lung Cancer | 768 | 2027-01-11 (+4 mo) |
| AZURE-LDL NCT07000123 |
P3 | Active, not recruiting | Cardiovascular Disease | 3103 | 2027-01-11 (-2 mo) |
| ESSENCE NCT06706817 |
P3 | Active, not recruiting | Chronic Rhinosinusitis With Nasal Polyps | 181 | 2027-01-13 |
| SOUND NCT05374603 |
P2 | Active, not recruiting | Lung Cancer | 47 | 2027-01-18 (+39 mo) |
| CONTEMPO NCT06151964 |
P1/2 | Active, not recruiting | Overweight and Obesity | 166 | 2027-01-29 (+25 mo) |
| Trastuzumab deruxtecan NCT06271837 |
P2 | Active, not recruiting | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | 127 | 2027-02-10 (+15 mo) |
| SERENIA NCT07215702 |
P2 | Recruiting | Sepsis; Acute Kidney Injury | 124 | 2027-02-11 |
| Zibotentan/Dapagliflozin NCT06087835 |
P3 | Active, not recruiting | Chronic Kidney Disease With High Proteinuria | 1835 | 2027-02-18 (-5 mo) |
| Rosuvastatin Dose 1 NCT06834932 |
P2/3 | Active, not recruiting | Dyslipidaemia | 432 | 2027-02-22 (+20 mo) |
| ROSY-T NCT05629234 |
P3 | Active, not recruiting | Cancer | 37 | 2027-02-22 (+11 mo) |
| IRIS NCT05138133 |
P3 | Active, not recruiting | Lupus Nephritis | 363 | 2027-02-23 (+16 mo) |
| PEAK NCT06749457 |
P1/2 | Active, not recruiting | Staphylococcus Aureus | 242 | 2027-03-08 (+5 mo) |
| DPT02 NCT04482309 |
P2 | Active, not recruiting | Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer; Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer | 477 | 2027-03-23 (+48 mo) |
| AZD4360 NCT06921928 |
P1/2 | Active, not recruiting | Gastric Cancer; Gastroesophageal Junction Cancer | 31 | 2027-03-31 (-4 mo) |
| ROSY-O NCT04421963 |
P3 | Active, not recruiting | Ovarian Cancer; Breast Cancer | 185 | 2027-04-06 (+24 mo) |
| BalanceD-HF NCT06307652 |
P3 | Recruiting | Heart Failure and Impaired Kidney Function | 3850 | 2027-04-16 (-2 mo) |
| PRISM NCT07285213 |
P2 | Recruiting | Clostridioides Difficile Infection | 230 | 2027-04-20 |
| CAMBRIA-1 NCT05774951 |
P3 | Recruiting | Breast Cancer, Early Breast Cancer | 4300 | 2027-04-20 |
| Trastuzumab deruxtecan NCT04784715 |
P3 | Active, not recruiting | Breast Cancer; HER2-positive; Metastatic | 1157 | 2027-05-03 (+21 mo) |
| DG-03 NCT04379596 |
P2 | Active, not recruiting | Gastric Cancer | 452 | 2027-05-04 (+52 mo) |
| PETRA NCT04644068 |
P1/2 | Active, not recruiting | Ovarian Cancer; Breast Cancer | 702 | 2027-05-28 (+22 mo) |
| laroprovstat/rosuvastatin 1 NCT07619118 |
P3 | Recruiting | Hypercholesterolaemia | 200 | 2027-05-28 |
| Umbriel NCT06932263 |
P2 | Recruiting | Asthma | 540 | 2027-06-07 (-1 mo) |
| ARRIVAL NCT06473779 |
P3 | Active, not recruiting | Severe Asthma | 310 | 2027-06-25 |
| KUNLUN NCT04550260 |
P3 | Active, not recruiting | Esophageal Squamous Cell Carcinoma | 640 | 2027-06-30 (+24 mo) |
| RHEA-1 NCT06795022 |
P1/2 | Recruiting | Hepatocellular Carcinoma | 304 | 2027-06-30 (-7 mo) |
| CANTOR NCT06792695 |
P2 | Active, not recruiting | Metastatic Colorectal Cancer | 82 | 2027-06-30 (+3 mo) |
| CYCAD-1 NCT06188520 |
P1/2 | Active, not recruiting | ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC) | 55 | 2027-06-30 (+24 mo) |
| BRAVO NCT07610837 |
P2 | Recruiting | Liver Fibrosis; Hepatic Cirrhosis | 104 | 2027-07-07 |
| MAJIC NCT05057494 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 607 | 2027-07-15 (-15 mo) |
| BaxPA NCT07007793 |
P3 | Active, not recruiting | Primary Hyperaldosteronism | 212 | 2027-07-27 (-7 mo) |
| Dato-DXd NCT06103864 |
P3 | Recruiting | Breast Cancer | 625 | 2027-07-28 (+10 mo) |
| Laroprovstat NCT07619131 |
P3 | Recruiting | Hypercholesterolaemia | 600 | 2027-07-30 |
| eVOLVE-01 NCT06448754 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer | 194 | 2027-07-30 (+23 mo) |
| ADAURA2 NCT05120349 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer | 390 | 2027-08-02 |
| PRESTO NCT07082738 |
P2 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 987 | 2027-08-31 (-2 mo) |
| Dato-DXd NCT05629585 |
P3 | Active, not recruiting | Breast Cancer | 1174 | 2027-09-01 |
| AZD8205 NCT05123482 |
P1/2 | Recruiting | Breast Cancer; Biliary Tract Carcinoma | 460 | 2027-09-29 (+28 mo) |
| EvoPAR-PR01 NCT06120491 |
P3 | Active, not recruiting | Metastatic Castration-Sensitive Prostate Cancer | 1898 | 2027-09-30 (-3 mo) |
| OSTARA NCT05801029 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer (NSCLC) | 60 | 2027-10-01 |
| Datopotamab deruxtecan (Dato-DXd) NCT05489211 |
P2 | Recruiting | Endometrial Cancer; Gastric Cancer | 454 | 2027-10-01 (+28 mo) |
| DURGA-1 NCT05850234 |
P1/2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 232 | 2027-10-01 (+19 mo) |
| APPRECIATE NCT06824987 |
P2 | Active, not recruiting | APOL1-Mediated Kidney Disease | 63 | 2027-10-04 |
| BAIYUN NCT06471257 |
P3 | Recruiting | Asthma | 1000 | 2027-10-04 (+11 mo) |
| Laroprovstat NCT07930507 |
P3 | Not yet recruiting | Hypercholesterolemia | 204 | 2027-10-11 |
| ACADIA NCT06307665 |
P3 | Recruiting | Asthma | 440 | 2027-10-13 |
| Puxitatug Samrotecan NCT07044336 |
P3 | Recruiting | Endometrial Cancer; Malignant Solid Tumour | 800 | 2027-10-15 |
| CAPItello-292 NCT04862663 |
P3 | Active, not recruiting | Locally Advanced (Inoperable) or Metastatic Breast Cancer | 893 | 2027-11-01 (+36 mo) |
| AVANZAR NCT05687266 |
P3 | Active, not recruiting | NSCLC | 1350 | 2027-11-01 (+5 mo) |
| TILIA NCT05624450 |
P3 | Recruiting | Viral Lung Infection and Acute Respiratory Failure | 3527 | 2027-11-04 (+42 mo) |
| Sonesitatug Vedotin NCT07069712 |
P2 | Recruiting | Gastroesophageal Adenocarcinoma | 100 | 2027-11-09 (+11 mo) |
| LaunchPAD-RA NCT07276581 |
P2 | Recruiting | Rheumatoid Arthritis | 320 | 2027-11-12 |
| CRIUS-1 NCT07529717 |
P1/2 | Recruiting | Metastatic Prostate Cancer | 42 | 2027-11-17 |
| eVOLVECervical NCT06079671 |
P3 | Recruiting | Locally Advanced Cervical Cancer | 800 | 2027-11-26 (+9 mo) |
| Rilvegostomig NCT05702229 |
P2 | Recruiting | Gastric Cancer | 163 | 2027-11-30 (+41 mo) |
| SPRINKLE NCT05309668 |
P1/2 | Active, not recruiting | Neurofibromatosis Type 1 | 36 | 2027-11-30 (+49 mo) |
| CAPItana NCT06764186 |
P3 | Active, not recruiting | Locally Advanced or Metastatic Breast Cancer | 101 | 2027-11-30 (-1 mo) |
| THARROS NCT06283966 |
P3 | Recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 5250 | 2027-12-03 (-3 mo) |
| CLEAR NCT07088926 |
P2 | Recruiting | Bronchiectasis With Pseudomonas Aeruginosa Colonization | 435 | 2027-12-09 |
| ATHENA NCT06084884 |
P1/2 | Active, not recruiting | Hepatocellular Carcinoma | 94 | 2027-12-13 |
| SERENA-1b NCT07427394 |
P2 | Recruiting | Advanced Breast Cancer | 24 | 2027-12-28 |
| SOUND-MCL NCT07029737 |
P2 | Recruiting | Mantle-cell Lymphoma | 55 | 2027-12-31 (+7 mo) |
| SYRUS NCT06137118 |
P1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 255 | 2028-01-06 (+23 mo) |
| JASMINE NCT06455449 |
P3 | Recruiting | Polymyositis, Dermatomyositis | 240 | 2028-01-10 (+8 mo) |
| BREEZE NCT07774403 |
P2 | Recruiting | Bronchiectasis With Pseudomonas Aeruginosa Colonization | 84 | 2028-01-18 |
| AZD0305 NCT06106945 |
P1/2 | Recruiting | Multiple Myeloma | 226 | 2028-01-24 (+27 mo) |
| TB06 NCT07205822 |
P3 | Recruiting | Breast Cancer | 100 | 2028-02-02 |
| TAPER NCT07363642 |
P3 | Recruiting | Severe Asthma | 400 | 2028-02-07 |
| CERTIS1 NCT05417594 |
P1/2 | Recruiting | Advanced Solid Malignancies | 695 | 2028-02-07 (+46 mo) |
| BaxNoD NCT07686120 |
P3 | Recruiting | Uncontrolled Hypertension | 286 | 2028-02-09 |
| CLIPS NCT06512883 |
P3 | Recruiting | Eosinophilic Granulomatosis With Polyangiitis (EGPA); Hypereosinophilia Syndrome (HES) | 14 | 2028-02-20 (+14 mo) |
| AURORA NCT07295847 |
P1/2 | Recruiting | Systemic Sclerosis; Idiopathic Inflammatory Myopathies | 27 | 2028-02-22 |
| Baxdrostat/dapagliflozin NCT06268873 |
P3 | Active, not recruiting | Chronic Kidney Disease and Hypertension | 2554 | 2028-02-24 (+2 mo) |
| BIFANG NCT07520162 |
P3 | Recruiting | Chronic Rhinosinusitis With Nasal Polyps | 230 | 2028-03-01 |
| IVOLGA NCT06943833 |
P2 | Active, not recruiting | Locally Advanced Cervical Cancer | 37 | 2028-03-13 |
| TROPION-Lung14 NCT06350097 |
P3 | Recruiting | Non-small Cell Lung Cancer | 582 | 2028-03-21 |
| Elecoglipron NCT07775404 |
P3 | Recruiting | Obesity; Overweight | 351 | 2028-04-06 |
| SOUNDTRACK-B NCT06526793 |
P2 | Recruiting | B-cell Non-Hodgkin Lymphoma; Follicular Lymphoma (FL) | 270 | 2028-04-21 (+14 mo) |
| Eluminate-2 NCT07662213 |
P3 | Recruiting | Type 2 Diabetes Mellitus | 1200 | 2028-05-23 |
| Eluminate-3 NCT07664553 |
P3 | Recruiting | Type 2 Diabetes Mellitus | 600 | 2028-05-23 |
| HORIZON NCT06023589 |
P3 | Recruiting | Asthma | 231 | 2028-05-31 (+13 mo) |
| ARTEMIDE-01 NCT04995523 |
P1/2 | Active, not recruiting | Non-Small-Cell Lung Carcinoma | 212 | 2028-06-01 (+55 mo) |
| DESTINY-BTC01 NCT06467357 |
P3 | Recruiting | Biliary Tract Cancer | 620 | 2028-06-12 (+2 mo) |
| DURGA-4 NCT07391657 |
P3 | Recruiting | Relapsed Refractory Multiple Myeloma | 508 | 2028-06-14 |
| Lumi-NHL NCT07123454 |
P1/2 | Recruiting | B-cell Non-Hodgkin Lymphoma | 164 | 2028-07-04 (+4 mo) |
| Eluminate-5 NCT07662109 |
P3 | Recruiting | Type 2 Diabetes Mellitus | 2000 | 2028-07-05 |
| Eluminate-4 NCT07662135 |
P3 | Recruiting | Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease | 900 | 2028-07-13 |
| Eluminate-1 NCT07662044 |
P3 | Recruiting | Type 2 Diabetes Mellitus | 800 | 2028-07-14 |
| Embold NCT07667803 |
P3 | Recruiting | Weight Management | 4500 | 2028-07-31 |
| FONTANA NCT05797168 |
P1/2 | Recruiting | Ovarian Cancer; Lung Adenocarcinoma | 622 | 2028-08-04 (+10 mo) |
| SELENE 2 NCT07784270 |
P3 | Recruiting | Obesity or Overweight; Diabetes Mellitus, Type 2 | 1500 | 2028-08-09 |
| SELENE 3 NCT07776509 |
P3 | Recruiting | Obesity or Overweight; Weight-Related Comorbidity | 500 | 2028-08-09 |
| SELENE 1 NCT07784725 |
P3 | Recruiting | Obesity or Overweight | 2500 | 2028-08-11 |
| LOTUS NCT07751848 |
P3 | Recruiting | Lupus Erythematosus, Systemic | 417 | 2028-08-25 |
| Durvalumab NCT06960577 |
P2 | Recruiting | Urinary Bladder Neoplasms; Immune Checkpoint Inhibitors | 150 | 2028-08-30 (-2 mo) |
| SELENE-Asia NCT07922330 |
P3 | Not yet recruiting | Obesity; Overweight | 330 | 2028-09-15 |
| ARGiNAUT NCT07652658 |
P2 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 359 | 2028-09-18 |
| TREVI-OC-03 NCT07816666 |
P3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer; Platinum-sensitive Relapsed Fallopian Tube Cancer | 600 | 2028-09-29 |
| BLOSSOM NCT05835310 |
P3 | Recruiting | Systemic Lupus Erythematosus | 100 | 2028-10-05 (-12 mo) |
| ALLight NCT07109219 |
P1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 83 | 2028-10-11 (+5 mo) |
| CLEAR-AbKD NCT07571746 |
P2 | Recruiting | Primary Membranous Nephropathy | 43 | 2028-10-13 |
| PACIFIC-4 NCT03833154 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 724 | 2028-10-31 (+61 mo) |
| TrAVeRse NCT05951959 |
P2 | Active, not recruiting | Mantle Cell Lymphoma (MCL) | 108 | 2028-10-31 (+5 mo) |
| DURGA-6 NCT07735637 |
P3 | Recruiting | Newly Diagnosed Multiple Myeloma (NDMM) | 750 | 2028-11-02 |
| eVOLVE-Meso NCT06097728 |
P3 | Active, not recruiting | Unresectable Pleural Mesothelioma | 863 | 2028-11-16 (+19 mo) |
| TREVI-OC-01 NCT07218809 |
P3 | Recruiting | Epithelial Ovarian Cancer | 1100 | 2028-11-17 |
| Dato-DXd NCT06112379 |
P3 | Active, not recruiting | Breast Cancer | 1902 | 2028-11-20 (+8 mo) |
| DUoENDE NCT06746116 |
P3 | Active, not recruiting | Advanced or Recurrent Endometrial Cancer | 45 | 2028-11-30 |
| eVOLVE-02 NCT06535607 |
P2 | Recruiting | Sub-study 1 Cervical Cancer (Volrustomig Monotherapy); Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) | 257 | 2028-11-30 (+27 mo) |
| PRIMROSE NCT06130553 |
P1/2 | Recruiting | Advanced Solid Tumors That Are MTAP Deficient | 334 | 2028-12-04 (+33 mo) |
| PATAGONIA NCT07941609 |
P2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | 2028-12-16 |
| ROMEO NCT07566195 |
P3 | Recruiting | Chronic Obstructive Pulmonary Disease; COPD | 59 | 2028-12-29 |
| Rilvegostomig NCT06109779 |
P3 | Active, not recruiting | Biliary Tract Cancer | 760 | 2029-01-02 (-6 mo) |
| DURGA-5 NCT07764978 |
P3 | Recruiting | Newly Diagnosed Multiple Myeloma | 750 | 2029-01-11 |
| SEACLIFF NCT07181161 |
P1/2 | Recruiting | Metastatic Prostate Cancer | 283 | 2029-01-18 |
| DE-01 NCT06989112 |
P3 | Recruiting | Endometrial Cancer | 600 | 2029-01-19 |
| SUNFLOWER NCT07430306 |
P3 | Recruiting | Systemic Lupus Erythematosus | 245 | 2029-01-26 |
| TROPION-Lung17 NCT07291037 |
P3 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 400 | 2029-01-29 |
| ATTRiumph NCT07608354 |
P2 | Active, not recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 326 | 2029-02-06 |
| MOMENTUM NCT07155226 |
P1/2 | Recruiting | Acute Lymphoblastic Leukaemia; Acute Myeloid Leukaemia | 85 | 2029-02-15 (-4 mo) |
| ALTAIR NCT06996782 |
P1/2 | Recruiting | Advanced or Metastatic Non-small Cell Lung Cancer | 152 | 2029-02-23 (+2 mo) |
| SERAFA-1 NCT07647328 |
P3 | Recruiting | ER-Positive HER2-Negative Breast Cancer | 150 | 2029-02-28 |
| JOURNEY NCT06878261 |
P3 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 990 | 2029-03-13 |
| EMBARK NCT06883305 |
P3 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 990 | 2029-03-13 |
| AZD5863 NCT06005493 |
P1/2 | Recruiting | Gastric Cancer; Gastro-esophageal Junction Cancer | 392 | 2029-03-16 (+27 mo) |
| ACTIVATED-4-PC NCT07192614 |
P1/2 | Recruiting | Prostate Cancer | 52 | 2029-03-29 |
| LIBRA NCT07098338 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 278 | 2029-04-06 (+31 mo) |
| ACRUE NCT05952024 |
P2 | Recruiting | Diffuse Large B-Cell Lymphoma | 80 | 2029-04-22 (+23 mo) |
| Rilvegostomig NCT06764875 |
P3 | Recruiting | HER2-positive Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | 840 | 2029-04-27 |
| MAVRiC NCT07024706 |
P2 | Recruiting | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | 80 | 2029-05-01 (-43 mo) |
| AZD0120 NCT06897930 |
P1/2 | Recruiting | Lupus Erythematosus, Systemic | 150 | 2029-05-01 |
| PRIMAVERA NCT06137144 |
P1/2 | Recruiting | Lymphoma; Non-Hodgkin Lymphoma | 161 | 2029-05-03 (+38 mo) |
| FAROS NCT07525375 |
P2 | Recruiting | Asthma | 69 | 2029-05-23 |
| NSCLC NCT07295821 |
P2 | Recruiting | Lung Cancer | 60 | 2029-05-30 |
| VECTRA-01 NCT07611110 |
P3 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 670 | 2029-06-04 |
| ALBORAN NCT06992609 |
P3 | Active, not recruiting | Small Cell Lung Carcinoma | 71 | 2029-06-30 |
| Osimertinib NCT05546866 |
P2 | Active, not recruiting | Non-small Cell Lung Cancer | 51 | 2029-06-30 |
| SOLAIR NCT07934420 |
P3 | Not yet recruiting | Asthma | 216 | 2029-07-30 |
| AB02 NCT07221253 |
P3 | Recruiting | Biliary Tract Cancer | 1100 | 2029-07-31 |
| Sonesitatug vedotin NCT07431281 |
P3 | Recruiting | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | 2130 | 2029-08-16 |
| Elevate-HF NCT07761117 |
P3 | Recruiting | Heart Failure With Preserved Ejection Fraction (HFpEF); Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | 6950 | 2029-09-03 |
| PROSPECTOR NCT07590934 |
P1/2 | Recruiting | Metastatic Prostate Cancer | 152 | 2029-09-25 |
| AZD6750 NCT07115043 |
P1/2 | Recruiting | Melanoma; Non-small Cell Lung Cancer | 120 | 2029-10-02 (+6 mo) |
| CT204V NCT07932496 |
P1/2 | Not yet recruiting | Relapsed or Refractory B-Cell Malignancies | 160 | 2029-10-15 |
| AZURE-Outcomes NCT07000357 |
P3 | Recruiting | Cardiovascular Disease | 15100 | 2029-10-26 |
| FLOT Chemotherapy NCT07877818 |
P3 | Recruiting | Gastric; Esophagogastric Junction | 140 | 2029-11-01 |
| TARGET NCT05526755 |
P2 | Active, not recruiting | Stage II-IIIB Non-small Cell Lung Carcinoma | 188 | 2029-11-22 (+5 mo) |
| Prevent-HF NCT06677060 |
P3 | Recruiting | Heart Failure | 11300 | 2029-12-17 |
| TITANium NCT06542250 |
P1/2 | Recruiting | B-cell Malignancies | 174 | 2029-12-18 (+22 mo) |
| BaxDuo-Pacific NCT06742723 |
P3 | Recruiting | Chronic Kidney Disease and Hypertension | 5000 | 2029-12-18 (-4 mo) |
| EvoPAR-BR01 NCT06380751 |
P3 | Recruiting | Advanced Breast Cancer | 788 | 2029-12-18 (+9 mo) |
| ROSY-F NCT07444567 |
P3 | Recruiting | Asthma; Eosinophilic Granulomatosis With Polyangiitis (EGPA) | 230 | 2029-12-27 |
| TROPION-Lung10 NCT06357533 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 675 | 2029-12-28 (-5 mo) |
| ARTEMIDELung04 NCT06868277 |
P3 | Recruiting | Carcinoma, Non-Small Cell Lung | 830 | 2030-01-17 |
| PEDZ-K NCT03813407 |
P3 | Recruiting | Hyperkalaemia | 140 | 2030-02-21 (+109 mo) |
| CAMBRIA-2 NCT05952557 |
P3 | Active, not recruiting | Breast Cancer, Early Breast Cancer | 5511 | 2030-03-04 (+1 mo) |
| ARTEMIDE-HCC01 NCT06921785 |
P3 | Recruiting | Hepatocellular Carcinoma | 1220 | 2030-03-15 (+12 mo) |
| PARTHENON NCT07446855 |
P1/2 | Recruiting | Solid Tumours | 180 | 2030-03-29 |
| eVOLVE-HNSCC NCT06129864 |
P3 | Recruiting | Locally Advanced Head and Neck Squamous Cell Carcinoma | 1145 | 2030-04-17 (+15 mo) |
| Soundtrack-E NCT06564038 |
P1/2 | Recruiting | Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma | 408 | 2030-05-20 (-8 mo) |
| NeoCOAST-2 NCT05061550 |
P2 | Recruiting | Non-small Cell Lung Cancer | 630 | 2030-05-28 (+63 mo) |
| SOUNDTRACK-D2 NCT07215585 |
P3 | Recruiting | Large B-cell Lymphoma | 420 | 2030-06-10 |
| TREVI-OC-02 NCT07851025 |
P3 | Recruiting | Epithelial Ovarian Cancer | 950 | 2030-06-28 |
| Balcinrenone/dapagliflozin NCT07624305 |
P3 | Recruiting | Renal Insufficiency, Chronic | 2800 | 2030-07-01 |
| Rilvegostomig NCT06692738 |
P3 | Recruiting | Non-small Cell Lung Cancer | 1160 | 2030-07-01 (+17 mo) |
| Anifrolumab + APFS NCT07630714 |
P2 | Recruiting | Systemic Lupus Erythematosus | 24 | 2030-09-02 |
| Soundtrack D3 NCT07911553 |
P3 | Not yet recruiting | Large B-cell Lymphoma | 1200 | 2030-09-02 |
| TU-04 NCT07720284 |
P3 | Recruiting | High-risk Muscle Invasive Urothelial Carcinoma | 915 | 2030-09-11 |
| Elevate-CKD NCT07753993 |
P3 | Recruiting | Chronic Kidney Disease | 7000 | 2030-10-04 |
| Rilvegostomig NCT06627647 |
P3 | Recruiting | Non-squamous Non-small Cell Lung Cancer | 1160 | 2030-11-18 (+18 mo) |
| AZD4045 NCT07681596 |
P1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 101 | 2031-03-06 |
| PETRANHA NCT05367440 |
P1/2 | Active, not recruiting | Metastatic Prostate Cancer | 174 | 2031-04-11 (+87 mo) |
| EvoPAR-PR05 NCT07711002 |
P3 | Recruiting | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 1330 | 2031-05-30 |
| SOUNDTRACK-C1 NCT07509151 |
P3 | Recruiting | Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | 420 | 2031-08-29 |
| Surovatamig NCT06549595 |
P3 | Recruiting | Untreated Follicular Lymphoma | 1018 | 2031-11-26 (+7 mo) |
| ROSY-S NCT07691970 |
P3 | Recruiting | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus | 1072 | 2032-12-30 |
| EvoPAR-PR02 NCT06952803 |
P3 | Recruiting | Prostate Cancer | 700 | 2033-03-31 |